GURUFOCUS.COM » STOCK LIST » Financial Services » Insurance » Hubei Biocause Pharmaceutical Co Ltd (SZSE:000627) » Definitions » Asset Impairment Charge

Hubei Biocause Pharmaceutical Co (SZSE:000627) Asset Impairment Charge : ¥0 Mil (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Hubei Biocause Pharmaceutical Co Asset Impairment Charge?

Hubei Biocause Pharmaceutical Co's Asset Impairment Charge for the three months ended in Mar. 2024 was ¥0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0 Mil.


Hubei Biocause Pharmaceutical Co Asset Impairment Charge Historical Data

The historical data trend for Hubei Biocause Pharmaceutical Co's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Biocause Pharmaceutical Co Asset Impairment Charge Chart

Hubei Biocause Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hubei Biocause Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hubei Biocause Pharmaceutical Co Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.


Hubei Biocause Pharmaceutical Co Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Hubei Biocause Pharmaceutical Co's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


Hubei Biocause Pharmaceutical Co (SZSE:000627) Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, Building 1, No. 1 Tianshan Road, Guohua Huijin Center, Zhanghe New District, Hubei Province, Jingmen, CHN, 448000
Hubei Biocause Pharmaceutical Co Ltd is a China-based company engaged in life insurance, health insurance, accident insurance, and other life insurance businesses, medicine, and chemical businesses. The company generates its revenue in the form of premiums.
Executives
Jiang Hai Hua Independent director
Fu Yong Jin Directors, executives
Wu Shi Yan Supervisors

Hubei Biocause Pharmaceutical Co (SZSE:000627) Headlines

No Headlines